Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-09, Vol.389 (11), p.998-1008
Hauptverfasser:	Loomba, Rohit, Sanyal, Arun J., Kowdley, Kris V., Bhatt, Deepak L., Alkhouri, Naim, Frias, Juan P., Bedossa, Pierre, Harrison, Stephen A., Lazas, Donald, Barish, Robert, Gottwald, Mildred D., Feng, Shibao, Agollah, Germaine D., Hartsfield, Cynthia L., Mansbach, Hank, Margalit, Maya, Abdelmalek, Manal F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy Biopsy Cholesterol Diabetes Diarrhea Double-Blind Method Electrocardiography Endocrinology Fatty liver Fibroblast Growth Factors - analogs & derivatives Fibrosis Fibrosis - drug therapy Fibrosis - etiology Fibrosis - pathology Gastroenterology Gastroenterology General Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - therapeutic use High density lipoprotein Humans Hypertriglyceridemia Immunology Inflammation Inflammatory Disease Injections, Subcutaneous International organizations Liver cirrhosis Liver Disease Liver diseases Magnetic resonance imaging Metabolism Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - pathology Obesity Placebos Treatment Outcome Vital signs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!